Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Luis Leon Mateos"'
Autor:
Almudena Zapatero, Antonio Gómez-Caamaño, María Ángeles Cabeza Rodriguez, Laura Muinelo-Romay, Carmen Martin de Vidales, Alicia Abalo, Patricia Calvo Crespo, Luis Leon Mateos, Carlos Olivier, Lorena Vega Vega Piris
Publikováno v:
Radiation Oncology, Vol 15, Iss 1, Pp 1-7 (2020)
Abstract Background Circulating tumor cells (CTCs) are an established prognostic marker in castration-resistant prostate cancer but have received little attention in localized high-risk disease. We studied the detection rate of CTCs in patients with
Externí odkaz:
https://doaj.org/article/540c844ab6cc4c64ac57db8ed6e96e05
Autor:
Alicia Abalo, Laura Muinelo-Romay, Luis Leon Mateos, Almudena Zapatero, Antonio Gómez-Caamaño, Maria Angeles Cabeza Rodriguez, Patricia Calvo Crespo, Lorena Vega Vega Piris, C. Olivier, Carmen Martín de Vidales
Publikováno v:
Radiation Oncology (London, England)
Radiation Oncology, Vol 15, Iss 1, Pp 1-7 (2020)
Radiation Oncology, Vol 15, Iss 1, Pp 1-7 (2020)
Background Circulating tumor cells (CTCs) are an established prognostic marker in castration-resistant prostate cancer but have received little attention in localized high-risk disease. We studied the detection rate of CTCs in patients with high-risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71e48d5d4c4f55d7c52c90ded95153fa
http://europepmc.org/articles/PMC7268302
http://europepmc.org/articles/PMC7268302
Autor:
Urbano Anido Herranz, Sergio Vázquez Estévez, Martin Lázaro Quintela, Lucía Santomé Couto, Ovidio Fernandez Calvo, Sonia Maciá Escalante, Luis Leon Mateos, F.J. Afonso
Publikováno v:
Critical Reviews in Oncology/Hematology. 107:119-127
Prostate cancer is the most frequent cancer amongst men. Until recently, only two therapeutic options, initial androgen-deprivation therapy in patients without castration-resistant prostate cancer, with addition of docetaxel when the disease becomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9c9fac9211c881d6d83748f46e0096
https://doi.org/10.1016/j.critrevonc.2016.08.007
https://doi.org/10.1016/j.critrevonc.2016.08.007
Autor:
Martin Lázaro Quintela, Urbano Anido Herranz, Ovidio Fernandez Calvo, Sergio Vázquez Estévez, Luis M. Antón Aparicio, Luis Leon Mateos, F.J. Afonso, Sofia Rodriguez Martinez de LLano
Publikováno v:
RUC. Repositorio da Universidade da Coruña
instname
instname
Review [Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an improvement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4250d8b8591fa3af11167732ce5809
https://hdl.handle.net/2183/21994
https://hdl.handle.net/2183/21994
Second-line chemotherapy with weekly paclitaxel in patients with advanced non-small-cell lung cancer
Autor:
María Calvo Rodríguez, Sonia Candamio Folgar, Begoña Graña Suárez, Luis Leon Mateos, Juan Fernando Cueva Bañuelos, Maria Teresa Curiel Garcia, Francisco Javier Barón Duarte, Rafael López López
Publikováno v:
Revista de Oncología. 4:188-191
In this phase II study we assessed the activity and toxicity of weekly paclitaxel in second line treatment of non-small-cell lung cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b39683db7061c3fbb9b5dc896c834c2
https://doi.org/10.1007/bf02717674
https://doi.org/10.1007/bf02717674
Autor:
Lucía Santomé, Sergio Vázquez Estévez, Martin Lázaro Quintela, Luis M. Antón Aparicio, Luis Leon Mateos, Urbano Anido Herranz, Ovidio Fernandez Calvo, F.J. Afonso
Publikováno v:
RUC. Repositorio da Universidade da Coruña
instname
instname
[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d81b2d7f050bff7ba7772b957ce614
https://pubmed.ncbi.nlm.nih.gov/25638257
https://pubmed.ncbi.nlm.nih.gov/25638257
Autor:
Rafael López, Jorge García González, Luis Leon Mateos, Urbano Anido Herranz, MC Areses, Beatriz Bernárdez Ferrán
Publikováno v:
RUNA. Repositorio da Consellería de Sanidade e Sergas
Servizo Galego de Saúde (SERGAS)
Servizo Galego de Saúde (SERGAS)
Renal cell carcinoma (RCC) with sarcomatoid features has an aggressive course. There is no standard treatment for this histological subtype. Some authors have previously reported the use of chemotherapy, but the activity of new agents against renal c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ba51f081507f1e8269ee7454106b62
https://pubmed.ncbi.nlm.nih.gov/21560067
https://pubmed.ncbi.nlm.nih.gov/21560067
Autor:
Jorge García González, Carlos Aliste Santos, Luis Leon Mateos, José M. Suárez Peñaranda, Daniel Pérez Fentes, Rafael López
Publikováno v:
Actas Urológicas Españolas v.33 n.4 2009
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Resumen El carcinoma sarcomatoide de vejiga es una neoplasia de alto grado, que representa aproximadamente el 0,3% de todas las neoplasias vesicales y tiene su origen en las celulas transicionales de la vejiga. el carcinoma sarcomatoide se caracteriz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4cfea3ca2717cf35dcf2e15731b5d0a
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0210-48062009000400019
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0210-48062009000400019
Autor:
Enrique Gallardo Diaz, Albert Font, M Isabel Sáez, Aranzazu Gonzalez del Alba, Sergio Vazquez-Estevez, Carmen Santander, Enrique Grande, Javier Puente, Teresa Alonso, Daniel Castellano, María José Méndez-Vidal, Maria Piedad Fernandez Perez, Begoña Mellado, Ignacio Duran, Enrique Gonzalez-Billalabeitia, Ovidio Fernandez Calvo, Angel Rodriguez Sanchez, Miguel Angel Climent, Luis Leon Mateos
Publikováno v:
Journal of Clinical Oncology. 33:TPS5073-TPS5073
TPS5073 Background: Enzalutamide (E) is a newly authorized drug for metastatic CRPC. E inhibits binding of androgens to androgen receptors, nuclear translocation of activated receptors and DNA tran...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2067a61b2c2fb6740eb98529babb0ba
https://doi.org/10.1200/jco.2015.33.15_suppl.tps5073
https://doi.org/10.1200/jco.2015.33.15_suppl.tps5073
Autor:
María José Juan Fita, Constanza Maximiano Alonso, Daniel Castellano, Javier L. Puertas, Angel Rodriguez Sanchez, Alvaro Pinto, P. Borrega, Isabel Chirivella, Julio Jose Lambea Sorrosal, Edelmira Velez De Mendizabal, Jose-Luis Gonzalez-Larriba, Rocío García Domínguez, Luis Leon Mateos, Aranzazu Gonzalez del Alba, Martin Lázaro Quintela, José Carlos Villa Guzman, Jose Angel Arranz Arija, Begoña Perez-Valderrama, Gustavo Rubio, Raquel Luque
Publikováno v:
Journal of Clinical Oncology. 33:e15597-e15597
e15597 Background: The IMRCC prognostic model for mRCC treated with VEGF-targeted agents (Heng, JCO '09) has been externally validated (Heng, Lancet Oncol '13), however, pt treated with Pz were not...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96d85fba1b059a620a46d7a2d6f55c4e
https://doi.org/10.1200/jco.2015.33.15_suppl.e15597
https://doi.org/10.1200/jco.2015.33.15_suppl.e15597